GL1X · GenesisL1 explorer

MolNFT v1 · #21753 · protein

Structure-based rational drug design: crystal structure of the complex formed between phospholipase A2 and a pentapeptide val-ala-phe-arg- ser

1SKG: “Structure-based rational drug design: crystal structure of the complex formed between phospholipase A2 and a…”. X-ray diffraction, 1 ligand (SO4). MolNFT v1 #21753 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
1SKG
Type
protein
Length
126 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Phospholipase A2; Vafrs
EC
3.1.1.4
Ligands
SO4

Structure

x-ray diffraction · 2 distinct chains · 46% helix, 8% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APhospholipase A2 (EC 3.1.1.4)protein12148% helix, 8% strand—
BVafrsprotein50% helix, 0% strand—

Ligands and binding sites

  • SO4 · Sulfate ion · ion · 4 copies · chains A
  • MOH · Methanol · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Interfaces

1 interface between chains.

  • A–B · 484 Ų buried · 7 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 7 disulfide (disulfide).

Compared structures

  • 1SKG · Structure-based rational drug design: Crystal structure of the complex formed between… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.